mRNA cancer vaccines have a secret weapon — and scientists just found it. Researchers at Washington University School of Medicine discovered that mRNA cancer vaccines activate a previously overlooked immune cell type (cDC2), not just the long-assumed cDC1 cells. This "backup" system helps explain why these vaccines are so potent and could guide the design of even more effective cancer treatments.
mRNA technology helped defeat COVID-19, and now scientists are racing to use it against cancer. A new study published in Nature from Washington University School of Medicine just flipped a key assumption about how these cancer vaccines actually work — and the discovery could make them significantly more powerful.
For years, researchers believed a specific immune cell called cDC1 was the essential driver behind mRNA cancer vaccines' tumor-fighting power. But when scientists ran experiments in mice without cDC1 cells, the vaccines still worked — tumors were cleared and strong immune responses were generated. A closely related cell called cDC2 stepped in as an unexpected contributor through a process called "cross-dressing," where it borrows protein fragments from other cells to activate tumor-killing T cells.
Key Takeaways:
Why it matters: mRNA cancer vaccines are already being tested against melanoma, lung cancer, and bladder cancer. Understanding the full immune machinery behind them gives researchers concrete targets to optimize these treatments — potentially improving outcomes for patients who don't respond well today.
